All Industries

Rail Vision score major US order advancing railway safety using its AI technology

Rail Vision Ltd

Rail Vision CEO Shahar Hania joined Steve Darling from Proactive to share exciting news about the company securing an order for its innovative AI-powered Switch Yard System from a Class 1 freight rail company in North America. This order, previously announced, marks a significant milestone for Rail Vision as it expands into the North American market and sets a new standard for safety and efficiency in rail operations. The freight rail company, one of the largest in North America, will install and evaluate the system on its locomotive to test various safety scenarios. Hania explained that Rail Vision's Switch Yard System utilizes electro-optic sensors combined with AI, machine learning, and Advanced Driver Assistance System solutions to address limited vision issues, extending the range of sight and reducing downtime. By enhancing punctuality, efficiency, and safety, the system aims to revolutionize rail operations. This announcement comes shortly after Rail Vision received another order for its AI-driven Switch Yard System from Loram, a leading US-based provider of railway track maintenance equipment and services. The order from Loram serves as a pilot project to integrate Rail Vision's advanced technology into Loram's rail track maintenance operations. This collaboration underscores both companies' commitment to advancing railway safety and operational efficiency. If the pilot project proves successful, Rail Vision and Loram will explore opportunities to expand their collaboration, potentially integrating Rail Vision's innovative solutions into Loram's service offerings across the United States. This strategic partnership highlights the potential for Rail Vision's technology to make a significant impact on the railway industry's safety and efficiency standards. Watch the full interview for more insights into Rail Vision's recent developments and its vision for the future of rail transportation. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

April 17, 2024 02:34 PM Eastern Daylight Time

Video

First Phosphate agrees to collaboration agreement with Pekuakamiulnuatsh First Nations

First Phosphate Corp

First Phosphate Corp CEO John Passalacqua and Vice President of Government Relations Armand Mackenzie joined Steve Darling from Proactive to announce the company and the local First Nations, Pekuakamiulnuatsh Takuhikan have announced the signing of a collaboration agreement with respect to its proposed phosphate mine and Lithium Iron Phosphate cathode active material plant project in the Saguenay-Lac-Saint-Jean Region of Quebec, Canada. The agreement sets out guidelines regarding employment opportunities, business horizons, environmental protection across the Nitassinan or ancestral lands, harmonization of exploration work with the members of the First Nation who occupy the Nitassinan, and the supervision of future work. Future access to the industrial park at Mashteuiatsh for Project development and financial participation in the Project by the First Nation are under consideration. The First Nation is also committed to collaborating with the Company in the establishment of rare igneous phosphate as a critical and strategic mineral at the Canadian federal levels of government. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

April 17, 2024 12:56 PM Eastern Daylight Time

Video

Fathom Nickel releases results from Q-1 drill program at Albert Lake Project

Fathom Nickel Inc

Fathom Nickel CEO Ian Fraser joined Steve Darling from Proactive to unveil the results of the Q1 drill program conducted at the company's Albert Lake Project. The program, characterized by the drilling of 6 holes totaling 1,386 meters, has yielded promising outcomes, with drillhole AL24077 intersecting 0.42% nickel over a significant intersection of 2.01 meters. A key highlight emphasized by Fraser is the nickel mineralization's host rock: orthopyroxenite. This particular geological formation is integral to the host rock assemblage identified at the nearby Rottenstone deposit, renowned for its exceptionally high-grade nickel, copper, and platinum group elements (PGE). The proximity of the mineralization to the historic Rottenstone deposit, located approximately 1.2 kilometers to the northeast, underscores the potential significance of this discovery. Of particular importance is the 10% nickel tenor defined in intervals comprising less than 3% sulphide in drillhole AL24077. This observation suggests the possibility of net-textured to massive sulphide mineralization occurring along strike, and potentially at depth, within the same ultramafic unit. If realized, this could pave the way for the development of a mineral deposit boasting metal grades akin to those of the historic Rottenstone deposit, marking a significant milestone in Fathom Nickel's exploration journey. Fraser also provided an update on drilling activities at the flagship Gochager Lake Project, noting that drilling has been successfully completed. Assay results from this drilling program are eagerly anticipated and are expected to be released by the end of May, providing further insights into the project's mineral potential and setting the stage for future exploration efforts. As Fathom Nickel continues to advance its exploration initiatives, these recent developments underscore the company's commitment to unlocking the full potential of its projects and delivering value to its stakeholders. Stay tuned for further updates as Fathom Nickel navigates the dynamic landscape of mineral exploration and continues to pursue its strategic objectives with vigor and determination. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

April 17, 2024 12:54 PM Eastern Daylight Time

Video

ARway.ai announces prestigious George Mason University sign up for company platform

ARway.ai

ARway.ai Chief Executive Officer Evan Gappelberg joined Steve Darling from Proactive to unveil an exciting development: George Mason University (GMU) has partnered with ARway.ai and is set to integrate the ARway platform into its campus infrastructure. As part of a visionary project slated for 2024, GMU will deploy ten spatial maps across its sprawling campus, revolutionizing campus navigation and enhancing the overall student experience. In his discussion with Proactive, Gappelberg highlighted the significance of this partnership, noting GMU's substantial undergraduate enrollment of approximately 27,014 students and the expansive campus spanning 817 acres. The scheduled deployment of ARway is poised to commence in early summer, affording the university ample time to rigorously test the platform's capabilities and gauge its efficacy before potentially implementing a full campus rollout in 2025. The ambitious plans for 2024 include an expansion of the augmented reality tour, empowering students to seamlessly locate and navigate to various offices and buildings across the campus. By leveraging ARway's innovative technology, GMU aims to enhance the accessibility of campus resources and elevate the overall student experience to unprecedented levels. Moreover, GMU has already taken proactive steps to share its pioneering experiences with ARway, having submitted several conference proposals to disseminate findings on this groundbreaking technology. Additionally, dedicated time has been allocated for further research and development efforts over the summer, underscoring GMU's commitment to harnessing cutting-edge tools to enrich the educational journey of its students. The enthusiasm at GMU for exploring the interactive capabilities of ARway is palpable. Preliminary beta testing has instilled confidence in the platform's potential to foster engagement and promote self-efficacy, both of which are integral to the long-term success of the college experience. As GMU embarks on this transformative journey with ARway.ai, the possibilities for innovation and advancement in campus navigation and student engagement are boundless. Stay tuned for more updates as GMU pioneers the integration of augmented reality into its campus ecosystem, setting new standards for educational technology and student empowerment. Contact Details Proactive United States +1 347-449-0879 action@proactiveinvestors.com

April 17, 2024 12:52 PM Eastern Daylight Time

Video

Lana Del Rey makes Coachella Grand Entrance on Ryvid Anthem Electric Motorcycle

Ryvid, Inc

The arrival of Lana Del Rey by motorcycle at her recent Coachella performance went viral over the weekend. However, there’s more to the story than meets the eye… Once the artist and her production team decided to create a dramatic entrance by arriving on the back of a motorcycle, they had to navigate a number of obstacles. For starters, the Fire Marshal wouldn’t allow conventional combustion engines to be used on safety grounds. They also stipulated the bikes couldn’t be ridden at more than 5mph. In fact, they needed assurances that the motorcycles couldn’t exceed that speed! Considering the stipulations, the production team quickly turned to the California-built Ryvid Anthem Electric Motorcycle. Firstly, its 4.3 kWh Battery Pack would ensure the performers and audience didn’t succumb to exhaust fumes. Secondly, Ryvid engineers were able to limit the Anthem to exactly 5mph through its electronic controller – reduced from the 75mph+ available for unrestricted use. And thirdly, the lightweight 313 lb Anthem – with its high-performance brakes, suspension and tires – allowed the riders to control the bikes with their standing passengers. And the Anthem’s low center of gravity made balancing with the passenger far easier than almost any other motorcycle, electric or otherwise. Undoubtedly, the Ryvid Anthem was the perfect bike for Lana and her production team. Priced at only $8,995 and available in six eye-catching colors, it’s also perfect for commuting and urban exploration. Equipped with an integrated charger, 75-mile range, two riding modes, modern styling, and much more, the Anthem is available for delivery now. For more information on the Ryvid Anthem and the soon-to-be-announced second Ryvid model, visit ryvid.com. Please note, a motorcycle license is required to ride the Anthem. ABOUT RYVID Ryvid is a cutting-edge manufacturing corporation in the high-growth field of Electric Light Vehicles. Founded by enthusiasts, engineered by innovators, and designed by aerospace industry gearheads, Ryvid’s mission is to create more sustainable and enjoyable personal mobility. The company name was derived by the merging of Rhythm and Avid; elements of motion and emotion that define the experience of using our products. With its first product – the Anthem – Ryvid produced a revolutionary, lightweight, affordable electric motorcycle with a significantly lower carbon footprint than its competitors. With the same innovation to be applied to upcoming models and variants, Ryvid is poised to revolutionize urban commuting. Ryvid products are designed and assembled in the United States. For further information, please visit ryvid.com The Ryvid Anthem is now available to reserve for delivery at $8,995 EDITOR’S NOTE A video of Lana Del Rey's arrival is available here: dropbox.com/scl/fi/dx87ujmgsut0zowjtzhfw/IMG_1843.mov?rlkey=khd53zce2d2euegomv08dtl5n&dl=0 Additional images are available here: dropbox.com/scl/fo/saflfj5am45fcsr581yqr/AGjCfQKvFpwbAQOUy_RAVgA?rlkey=bi8ogyysctrudcckxdslgvif6&dl=0 Editorial staff wishing to ride the Ryvid Anthem should please use the Media Contact below. Images and information on the Ryvid Anthem are available here. Anthem specifications are available here: ryvid.com/anthem/specs. A Ryvid Anthem video is available to view and share here: youtu.be/mAnhMf2A3J4 Contact Details Greg Emmerson greg@theidagency.com Company Website https://ryvid.com/

April 17, 2024 09:05 AM Pacific Daylight Time

Image

Ride the Crypto Bull Run: Dive into HTX's Enhanced Flexible Products and Dual Investment with Expanded Offerings, Enjoying Up to 10% APY

HTX

Bitcoin has tested the $70,000 mark several times, fueling persistent FOMO sentiment in the market, while an array of new protocols and staking opportunities emerge. In the current crypto bull market, HTX Earn offers a variety of robust products to help investors achieve financial growth. With distinct advantages, these products offer a diverse range of offerings, high APYs, and low entry barriers. Users can choose products based on their financial situation as each of HTX Earn's products has its features. Quick and Easy Access to Simple Earn, with Products Offering up to 10% APY HTX Earn's Flexible products are continuously broadening their selection to include more popular cryptocurrencies, empowering users to capitalize on the appreciation of high-quality cryptos while earning returns. Additionally, these Flexible products offer exceptional flexibility, allowing users to deposit and withdraw funds at their convenience. According to HTX's official announcement, HTX Earn has recently introduced new Flexible products for PEPE, BOME, SLERF, DEGEN, and WIF, boasting up to 10% APY. To subscribe to these products, you can access them either through HTX's official website or app. Please follow the steps below. Website: Log in to HTX's official website > click "Earn" on the navigation bar > select "Flexible, Fixed" in the dropdown menu. App: Log in to your HTX App > tap "Earn" on the main page > select "Simple Earn". Compared to Traditional Offerings, HTX's Structured Products Provide Higher Annualized Earnings HTX Structured Products is an innovative financial instrument that includes assets linked to fixed income and derivatives to meet the personalized needs of investors with different risk preferences and return expectations. These products feature higher APYs and zero fees, catering to users with risk tolerance, professional investors, and institutions. This category encompasses two products: Dual Investment and Shark Fin. Dual Investment is a non-principal-protected structured product that consists of two cryptocurrencies. It empowers investors with the flexibility to select a target price and date, allowing them to capitalize on opportunities to purchase the specified cryptocurrency at a lower price or sell it at a higher value in the future. The Dual Investment product is non-principal protected and generates floating earnings. It allows you to gain returns by investing in one of the cryptos, such as BTC, ETH, AVAX, and SOL. At present, HTX Earn has updated its Dual Investment products, adding LTC, DOT, LINK, and MATIC offerings. This expansion broadens the range of choices available to users. Shark Fin is the flagship product of HTX Earn, and its pattern can be either bullish or bearish. What sets Shark Fin apart is its unique ability to enable investors to secure basic returns while potentially pursuing more profits based on market fluctuations. Additionally, these products are characterized by flexibility and short investment cycles without affecting fund liquidity. Users' returns from Shark Fin are determined by the accuracy of their predictions about future market trends. During the first quarter of 2024, 15 rounds of 7-day Shark Fin products were issued, amassing a total subscription amount of $1.5 billion, with the highest APY reaching 60%. Users can make subscriptions by navigating to "HTX Earn" > "Shark Fin" during the subscription period. As a world-leading digital asset trading platform, HTX has maintained a secure operation for eleven years. HTX Earn serves as a dependable instrument for the management of virtual assets, presenting a wide range of products that align with users' requirements. It guarantees the utmost security of assets, thanks to the exchange's robust risk management system. Furthermore, HTX Earn is purpose-built to deliver top-tier assets for daily passive income, coupled with a user-friendly interface that ensures a seamless and convenient wealth management experience. About HTX Founded in 2013, HTX has evolved over a decade from a simple cryptocurrency exchange to a comprehensive blockchain business ecosystem. This expansion covers a wide range of services including digital asset trading, financial derivatives, wallets, research, investments, incubation, and more. As a world-leading portal to Web 3.0, HTX is committed to a growth strategy focused on global expansion, ecological prosperity, wealth effect, and safety and compliance. This approach enables us to offer comprehensive, safe, and reliable services and value to virtual currency enthusiasts around the world, reinforcing our position as a global gateway to Web3. Contact Details Michael Wang glo-media@htx-inc.com Company Website https://www.htx.com/

April 17, 2024 11:24 AM Eastern Daylight Time

News Release

TOWER CAPITAL GROUP Reveals Esteemed Multidisciplinary Generational Health Advisors

TOWER CAPITAL GROUP

TOWER CAPITAL GROUP, market maker of Generational Health, is proud to announce the addition of nine new members to its esteemed Advisory Team. Generational Health are those effects passed on genetically, epigenetically, and environmentally, shaping humanity’s evolutionary curve. It represents a multi trillion-dollar opportunity encompassing critical areas of community, environment, and women’s health. TOWER’s Advisory Team includes expertise across more than 10 industry categories including Digital Health, Energy, Life Sciences, Pharmacy, AI & Data, Veterans’ Health, Venture Capital, Women’s Health, and more. These experts come from across the United States and include Entrepreneurs, Strategic Operators, Corporate Executives, and Funders. The appointment of these industry leaders demonstrates the strategic and execution capacity of TOWER CAPITAL GROUP as it supports the growth of its published cohort of > $17B USD Generational Health entities, as measured by total current capital invested. As summarized by TOWER’s Capital Markets and Community expert, Philip Benjamin, “Generational Health supports a framework for my clinical and advocacy work in children’s health and safety with an understanding that their wellbeing extends to those that care for children, the community, and the environment at large.” Further shared by TOWER’s Medicine and Health Systems expert, Dr. Jennifer Kahoud, “As an ER doctor on the front lines of a broken city, we are not asking the right questions to bring about necessary change. A multidisciplinary approach to Generational Health is a bold call for accountability to ask and answer the right questions.” Additionally, Tom Cassels (Life Science & Digital Health), Stephanie Lasker (Operating Excellence for Scaling Startups), Charlie Lieu (Big Data & Systems Biology), Justin Nahama (Military & Veteran Health), Alpa Saluja (Clinical Insight), Naseem Sayani (Early Stage Venture Capital), and Dorothea Soule (Energy & Commercialization) all represent rigor and intelligence across the many disciplines of Generational Health. Operating across industries, regions and partners, TOWER CAPITAL GROUP and its affiliates deploy expertise and capital to uncover economic value, investment and innovation within Generational Health and bring it to stakeholders across the globe. Visit www.towercapital.org for more information on Generational Health, the Company, and its mission. Investor Inquiries: Sheri Bailey sheri@towercapital.org Contact Details For Media Inquiries please contact TOWER CAPITAL GROUP contact@towercapital.org

April 17, 2024 11:00 AM Eastern Daylight Time

MJ ATTACHÉ LAUNCHES BUSINESS WITH DEBUT OF FIRST-OF-ITS-KIND LUXURY CACHE-AND-CARRY BAG FOR CANNABIS CONNOISSEURS, IN TIME FOR APRIL 20, CANNABIS CELEBRATION DAY

MJ Attaché

MJ Attaché, a designer and developer of luxury Italian-made leather bags and accessories for the cannabis connoisseur, announced today the official launch of the business. The commencement of MJ Attaché is marked by the introduction of the first-of-its-kind, premium, 100% Italian leather bag, The Anthony, carefully curated for cannabis cache and carry. The Anthony’s debut comes just in time for April 20 th, a day when cannabis is celebrated. MJ Attaché’s bags are market-disrupting; they boast patent-pending modular elements -- not found in any other bag -- that encourage a personalized cannabis experience specific to each one’s individual consumption needs. Catering to both male and female cannabis users, The Anthony’s novel magnetic, re-attachable accessories are fully customizable. Elements inside the bag can be easily added or deleted, depending on what each user prefers for their cannabis self-care ritual. Cleverly crafted by hand in Florence, Italy of the finest Italian leather, The Anthony’s features distinguish it from any other cannabis carry-all bag currently available in the market. Available in five colors, The Anthony bag includes a secure lock closure, removable smooth leather rolling tray, modular elements for customization, such as a pipe case, lighter sleeve, jar sleeve a smell-proof glass jar and a removable, adjustable crossbody strap. The combination of the leather and smell-proof jar aids in disguising odors and keep contents discreet. The MJ Attaché brand challenges outdated, inaccurate stereotypes of cannabis consumers by offering mainstream users a way to elevate their cache-and-carry preferences and experiences. Cannabis has come a long way from its prior perceptions, and MJ Attaché recognizes its broader adoption by users spanning the spectrum. Like many entrepreneurs, ideas are often spurred by personal experience. MJ Attaché is no exception. Founder Christy Fuicelli created the brand and designed its premium bag when she was personally searching for a sophisticated, safe and discreet carry-all solution for her cannabis and accessories. She came up emptyhanded when shopping for options of the same high-quality, sophistication and style to which she was accustomed. Fuicelli believed this void in the marketplace stemmed from stigmas associated with overall cannabis use and she set out to change the market landscape with the design, development and introduction of The Anthony. “I went on a crusade to create a stylish, luxury, handcrafted bag many would be proud to carry. With its impeccable style, quality Italian leather components and customizable modular system, The Anthony bag transcends the outdated “stoner” stereotypes cannabis users are often perceived as and creates the ultimate luxury cannabis experience. I travelled on this journey witnessing nearly a dozen iterations of The Anthony until I was pleased because I could not find a functional, sophisticated, stylish and well-made cannabis transport option, which sparked my interest in developing one myself,” entrepreneur Fuicelli said. “Additionally, I was determined to challenge preconceived notions relating to cannabis use stereotypes. Many people use cannabis medicinally as well as to reduce stress and anxiety and promote relaxation. For me, my cannabis use not only helped alleviate certain medical conditions but also can be directly attributed to the deep creativity it ignited in me, sparking my idea for The Anthony and other bags and accessories in the MJ Attaché product line. I am hoping adoption of The Anthony and other MJ Attaché offerings will simplify the lives of cannabis users around the world. The Anthony truly marks an entry into a market where no other bag like it exists,” Fuicelli concluded. The Anthony, with a price point of $2,150.00, can be purchased here. Looking ahead, MJ Attaché is currently developing other cannabis bag styles and accessories, which are slated for introduction into the marketplace in the latter part of 2024. About MJ Attaché Denver-based MJ Attaché is a designer and developer of high-quality, handmade Italian leather bags and accessories for the cannabis connoisseur. The luxury brand, with its moniker MJ (short for Mary Jane an alias for marijuana), was founded by entrepreneur Christy Fuicelli, a stylish cannabis user. She realized a void in the marketplace to cache and carry her cannabis in a discreet manor reflective of the luxury she enjoyed in other personal products she owned and believed this stemmed from stigmas associated with cannabis use. Determined to bridge this gap, MJ Attaché was born. Fuicelli set out to create a premium bag that would appeal to both male and female cannabis users. She spent years designing and creating beautifully crafted bags that embody elevated style, sophistication, high quality and fine craftmanship. By bringing ease and style to the cannabis industry with her bags, MJ Attaché brings the first accessory of its kind, The Anthony bag, to the marketplace. For more information, visit www.mjattache.com and connect with the Company and its products on Facebook and Instagram. Contact Details PAIRELATIONS, LLC for MJ Attaché Susan J. Turkell +1 303-766-4343 sturkell@pairelations.com

April 17, 2024 10:00 AM Eastern Daylight Time

Image

Theriva Biologics Hits Several Milestones In 2023, Positioning Itself For Growth As The Firm Targets Difficult-To-Treat Cancers

Benzinga

By Meg Flippin, Benzinga Theriva™ Biologics (AMEX: TOVX), the clinical-stage immuno-oncology company developing therapies for difficult-to-treat cancers, hit several milestones during 2023, potentially positioning it for a strong year ahead. That could be good news for patients with pancreatic, retinoblastoma, head and neck, brain or ovarian cancers. If Theriva is right, its oncolytic viruses can overcome the protective barrier surrounding solid tumors and selectively kill tumor cells. Its developmental therapies are designed to enable systemic delivery – which means they can target the tumor and distant metastases and have the potential to enhance current standard-of-care therapies, the company says. Theriva’s oncolytic viruses can be administered intravenously or as a direct injection into the tumor or tumor compartment. Trials Underway Announcing its financial results for the full year 2023, Theriva reported ending the year in a good position with VCN-01, its lead therapy candidate. VCN-01 is currently in a phase 2b trial for the treatment of patients with pancreatic ductal adenocarcinoma (PDAC) and in investigator-sponsored studies in a number of indications. As of late March, dosing was underway and enrollment continues to progress for VIRAGE, the randomized, controlled, multicenter open-label phase 2b trial of VCN-01 in combination with standard-of-care chemotherapy as a first-line therapy in newly diagnosed metastatic PDAC patients. The trial is targeting enrollment of 92 evaluable patients and the company reports it's on track to complete enrollment in the first half of this year. Patients are being enrolled in six sites in the U.S. and nine in Spain and will continue without any changes to the protocol after an evaluation by the Independent Data Monitoring Committee (IDMC) found no safety concerns. Intravenous VCN-01 has been well tolerated and demonstrated a safety profile consistent with prior clinical trials, Theriva reports. Importantly, it said no additional toxicities were observed in patients receiving a second dose of VCN-01. That means repeated systemic dosing of VCN-01 is feasible from a safety perspective, paving the way for Theriva to focus on whether the repeated dose VCN-01 regimen may lead to improved clinical outcomes for patients. “We believe VCN-01’s differentiated mechanism of action has the potential to address the urgent need for new treatment options for patients with PDAC by degrading the tumor matrix and increasing tumor access by VCN-01 and co-administered cancer therapies,” said Theriva CEO Steven Shallcross during a conference call to discuss full year 2023 earnings. To date, more than 100 patients have been dosed with VCN-01 in clinical trials in patients with a broad range of cancers, including PDAC, retinoblastoma, colorectal cancer and head and neck squamous cell carcinoma (HNSCC). Additional investigator-sponsored studies have been initiated in patients with brain cancers and ovarian cancers. Beyond Pancreatic Cancer Treating pancreatic cancer with VCN-01 isn’t the only area Theriva focused on during the year. The company is also engaged in a phase 1 trial evaluating the safety and activity of intravitreal VCN-01 in pediatric patients with refractory retinoblastoma. That trial is making progress, with the company completing patient treatment. The trial is designed to evaluate escalating doses of VCN-01 administered by two intravitreal injections separated by 14 days. The investigator-sponsored phase 1 trial will complete patient follow-up in the first half of 2024, and the results will help inform the planned phase 2 trial design, Theriva says. Additionally, the University of Pennsylvania continues to enroll and treat patients in their phase 1 investigator-sponsored trial administering VCN-01 with huCART-meso cells to patients with ovarian or pancreatic cancers. VCN-01 is designed to increase tumor immunogenicity and improve access by additional therapies such as huCART-meso cells. Dosing is also underway for the ongoing phase 1b/2a randomized, double-blinded, placebo-controlled clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host-disease (aGVHD). Theriva said SYN-004 appears to be well tolerated. Collaborating And Expanding Partnerships Not one to rest, Theriva was also busy during the year expanding collaborations and identifying new areas that may benefit from VCN-01. Late last year it signed an exclusive option to license intellectual property from Sant Joan de Déu-Barcelona Children’s Hospital (SJD) to explore the therapeutic potential of VCN-01 in combination with topoisomerase I inhibitors. This strengthens a long-term research collaboration with SJD and builds on an ongoing trial evaluating VCN-01 in pediatric cancers. The company is also pursuing licensing discussions for its SYN-020 intestinal alkaline phosphatase asset. SYN-020 is a recombinant bovine intestinal alkaline phosphatase (IAP) formulated for oral delivery to the small intestine and designed to diminish fat absorption and intestinal inflammation, tighten the gut barrier to mitigate “leaky gut” and promote a healthy microbiome. It has the potential to become a multi-indication therapeutic capable of addressing disorders stemming from gastrointestinal (GI) inflammation. Theriva is doing all this and keeping costs down. For the year ended December 31, 2023, general and administrative expenses decreased 28% to $7.1 million from $9.9 million in the year-earlier period. Meanwhile, the company increased spending on research and development by 22%, with an eye on the future based on an observed uptick in demand for its compounds. “In 2023, we continue to make steady progress to drive forward our oncology-focused portfolio designed to address unmet needs for difficult-to-treat cancers,” said Shallcross on the earnings call. “Our primary efforts and resources are focused on pursuing multiple therapeutic opportunities for our lead clinical candidate VCN-01. We'll continue to look for ways to drive additional value for our shareholders and for the long-term success of what we're trying to do, namely delivering promising treatments for very, very difficult-to-treat cancers.” Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

April 17, 2024 08:30 AM Eastern Daylight Time

Image

1 ... 104 105 106 107 108 ... 3598

Back